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Background: In March 2020, the World Health Organization declared a global pandemic
due to the novel coronavirus SARS-CoV-2 and several governments planned a national
quarantine in order to control the virus spread. Acute psychological effects of quarantine in
frail elderly subjects with special needs, such as patients with dementia, have been poorly
investigated. The aim of this study was to assess modifications of neuropsychiatric
symptoms during quarantine in patients with dementia and their caregivers.
Methods: This is a sub-study of a multicenter nation-wide survey. A structured telephone
interview was delivered to family caregivers of patients with diagnosis of Alzheimer disease
(AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular
dementia (VD), followed regularly at 87 Italian memory clinics. Variations in behavioral and
psychological symptoms (BPSD) were collected after 1 month since quarantine
declaration and associations with disease type, severity, gender, and caregiver’s stress
burden were analyzed.
Results: A total of 4,913 caregivers participated in the survey. Increased BPSD was
reported in 59.6% of patients as worsening of preexisting symptoms (51.9%) or as new
onset (26%), and requested drug modifications in 27.6% of these cases. Irritability, apathy,
agitation, and anxiety were the most frequently reported worsening symptoms and sleepg September 2020 | Volume 11 | Article 5780151
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Frontiers in Psychiatry | www.frontiersin.ordisorder and irritability the most frequent new symptoms. Profile of BPSD varied according
to dementia type, disease severity, and patients’ gender. Anxiety and depression were
associated with a diagnosis of AD (OR 1.35, CI: 1.12–1.62), mild to moderate disease
severity and female gender. DLB was significantly associated with a higher risk of worsening
hallucinations (OR 5.29, CI 3.66–7.64) and sleep disorder (OR 1.69, CI 1.25–2.29), FTDwith
wandering (OR 1.62, CI 1.12–2.35), and change of appetite (OR 1.52, CI 1.03–2.25).
Stress-related symptoms were experienced by two-thirds of caregivers and were
associated with increased patients’ neuropsychiatric burden (p<0.0001).
Conclusion: Quarantine induces a rapid increase of BPSD in approximately 60% of
patients and stress-related symptoms in two-thirds of caregivers. Health services need to
plan a post-pandemic strategy in order to address these emerging needs.Keywords: behavioral and psychological symptoms, behavioral symptoms, psychological symptoms, quarantine,
dementia, caregiver, coronavirus disease, genderINTRODUCTION
An outbreak of a novel coronavirus (severe acute respiratory
syndrome coronavirus 2 -SARS-CoV-2) emerged in Wuhan,
China, in late 2019 and spread to Europe in February 2020 with
the first infected patient diagnosed in Italy. It has since then spread
globally, with over 10 million confirmed cases as of June 30, 2020.
SARS-CoV-2 has been identified as the cause of COVID-19, a
respiratory illness with heterogeneous systemic and neurological
symptoms (1–3). Older adults and subjects with higher
comorbidities have the lower prognosis (4) and presence of
dementia increases the risk of mortality after COVID-19 (5). For
the containment and management of COVID-19, government
authorities have introduced mitigation strategies based on
measures of lockdowns, travel restrictions, and mass quarantine.
Italy was the first European Country to impose a nationwide
lockdown on March 13, 2020.
Confinement and isolation have been proven to be highly
effective for the control of infectious diseases, including COVID-
19 pandemic (6). However, previous outbreaks of SARS andMERS
showed that quarantine has a negative effect onmental health, with
increased psychiatric symptoms particularly related to stress
reactions such as anxiety, depression, and anguish (7).
Considering findings from previous outbreaks and preliminary
observations during the COVID-19 pandemic, the scientific
community has launched an alarm about a possible imminent
“pandemic” of psychiatric disorders (8–10). Factors triggering an
increase of post-pandemic psychiatric disorders may be multiples.
Importance has been given to a direct effect of isolation, with
restrictions on movements, impoverishment of social contacts,
and affective relationships, perceived loneliness. Anxiety may
arise from the rapid need to adapt to new lifestyle and changes of
day todayroutines. Inaddition, an increased stateof alert due to fear
of contagion and grief or even mourning for the loss of family
members or friends for COVID-19 may undermine mental health
wellbeing (10).
These considerationsapply to thegeneral populationandvery few
information is available for the most vulnerable persons in society,g 2such as elderlies and those affected by dementia (11, 12). Individuals
with dementia are frail, dependent on caregivers for daily living
activities and needing the support of a network of social and health
services resources (memory clinics, Alzheimer café, diurnal centers,
physiotherapy, etc.). In this scenario, extended lockdown with
imposed self-isolation and change or deprivation of usual daily
activities may represent a stressor event in both patients and
caregivers with high risk to induce anxiety and depression (13).
Changes in neuropsychiatric symptoms in subjects with dementia
may exacerbate the psychological effects of lockdown in their
caregivers, situation which may further worsen patients’ behavioral
symptoms, acting in a vicious loop of mutual increase of psychiatric
burden. Finally, confinement reduces access to physical exercise or
even physiotherapy, and movement restriction exacerbates
symptoms of dementia (13, 14). In turn, lack of activities and
global cognitive and physical stimulation may cause delirium in
individualswithdementia, contributing further tomorbidity.There is
also increase evidence that psychological symptoms due to stressor
events can contribute to cognitive decline (15).
A call of action for a plan to evaluate and counteract mental
status illnesses in the COVID-19 post-pandemic phase in the
general population has been launched (16). However, knowledge
on the psychological effects of quarantine in patients with
dementia, at higher risk of mental health worsening, is lacking.
In this perspective, the aim of this study was to investigate the
frequency and type of changes in behavioral and psychological
symptoms of dementia (BPSD) during the first month of
COVID-19 quarantine in patients with different types of
brain diseases leading to dementia and the psychological effects
in their caregivers. Factors that may modulate the change in
neuropsychiatric symptoms such as disease type and severity,
patient’s gender, and caregiver’s stress were also investigated.METHODS
This is an observational sub-study nested in a larger multicenter
nation-wide survey conducted in Italy between 14 and 24 AprilSeptember 2020 | Volume 11 | Article 578015
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pandemic on cognitive, behavioral, and motor symptoms of
patients with dementia, impact of quarantine in family
caregivers, and changes of health services devoted to dementia
care. Here we report results regarding patients’ BPSD changes
and caregivers’ psychological symptoms.
Study Protocol
Eighty-seven Centers for Cognitive Disorders and Dementia
(CDCD) equally distributed among Northern, Center, and
Southern Italy were recruited. Invitation to participate in the
survey was made through two Italian scientific societies involved
in dementia care and research, the Italian Neurological Society
for Dementia (SINdem), and the Italian Association of
Psychogeriatrics (AIP), to all their participants working in the
CDCD. Eighty-nine centers responded positively and two centers
were not able to conclude the enrolment and therefore 87 finally
participated in the study. Patient’s response rate was 98%. Study
collaborators of each CDCD were asked to deliver by phone call a
semi-structured interview to family caregivers of patients with
dementia on regular clinical follow-up. Inclusion criteria were a)
a diagnosis of one of the most common forms of dementia
including: 1. Alzheimer’s disease (AD), 2. dementia with Lewy
bodies (DLB), 3. frontotemporal dementia (FTD), and 4. vascular
dementia (VD); b) presence of a family caregiver. Exclusion
criteria included a diagnosis of mild cognitive impairment and
primary psychiatric disorders. The semi-structured interview
was administered to family caregivers through a questionnaire
divided in two parts, regarding patients’ and caregivers’ features
(Supplementary Material). The part related to patients consisted
of nine questions regarding modifications of dementia-related
symptoms after beginning of quarantine and clinical data on
previous physical independence and awareness of current
pandemic. In particular, caregivers were asked whether patients
had worsened one or more of the following BPSD: irritability,
apathy, agitation, anxiety, depression, sleep disturbances,
aggressiveness, wandering, appetite change, hallucinations, and
delusions. In addition, the onset of new symptoms among the
abovementioned BPSD was enquired. A further question about the
need of drug treatments modifications due to worsened or new
BPSD was administered. The part related to family caregivers
explored 16 domains concerning demographic and social
characteristics, life style and work changes after quarantine, use of
medical care and health services for patients needs, and
psychological effects of pandemic. Each center was asked to
practice with the telephone-based interview before starting
recruiting. A person of the organizing committee was available to
solve questions or doubts risen from initial training. No formal
harmonized procedure of delivering the interview was planned.
The study was initially approved by the Ethics Committee of
the Coordinating Center (University of Torino on April 7, 2020,
n.00150/2020) and by the local ethics boards. Participants gave
informed consent to the study.
Statistical Analysis
The primary data source consists of all the interviews administered
(total sample = 4,913). A sub-sample of patients with BPSD changesFrontiers in Psychiatry | www.frontiersin.org 3(n= 2,929) was extracted, considering patients with BPSD changes
having either preexisting and/or new-onset symptoms. The fields
with missing values are approximately 0.6% for which no
substitution has been made.
EPI Info 7.2 software (EPIINFO ™, CDC, Atlanta, USA) was
used for the statistical analysis. Microsoft Excel (Microsoft Office
2019) was used to process the charts. Microsoft Access
(Microsoft Office 2019) was used to create the intermediate
analysis tables. The analysis of the descriptive frequencies and
the crude univariate logistic regression for the preexisting and
new BPSD symptoms were performed, stratifying where necessary
to control the confounding’s. Subsequently, unconditional and
matched logistic regressions were performed to assess the
dependence on the diagnosis, the degree of disease severity and
gender, setting the confidence limits at 95%.RESULTS
Patients’ Demographic and Clinical
Characteristics
Data were obtained through interview of 4,913 caregivers of
patients with dementia after a mean quarantine period of 47.2 ±
6.4 days. Patients’ demographic, social, and clinical characteristics
are reported in Table 1.
Patients had a diagnosis of AD in 69% of cases, VD in 16%,
FTD in 8%, and DLB in 7%. Mean age, disease duration, disease
severity, gender type, and geographical distributions of recruiting
centers were not different between disease groups.
Neuropsychiatric Symptoms Changes
Caregivers reported BPSD changes (worsening and/or new onset
BPSD) in 2,929 patients (59.6%) after 1-month from beginning
of quarantine. Worsening of preexisting BPSD was described in
51.9% of cases. The DLB group had the highest frequency of
increased BPSD (63.8%), followed by FTD (55.3%), AD (50.5%),
and VD (50.3%). Onset of new BPSD was reported in 25.9%, with
higher frequency in AD (26.7%) and lower in FTD (21.9%)
(Table 1).
Patients with DLB and BPSD changes had a wider burden of
neuropsychiatric symptoms (considering both worsened and
new symptoms) with almost 30% having three or more
symptoms, respect to FTD (21%) and AD and VD (both 19%)
(Figure 1).
The increased burden of BPSD required a modification of
drug treatments in 27.6% of patients with BPSD changes. In the
multivariate analysis frequency of neuropsychiatric symptoms
was not associated with patient’s age, gender, type of dementia,
severity, and duration of the disease.
As far as the type of BPSD, the most frequently reported
worsened BPSD was irritability (40.2%), followed by apathy
(34.5%), agitation (30.7%), anxiety (29%), depression (25.1%),
and sleep disorder (24%). The less frequently reported BPSD
were in the psychotic domain, with both hallucinations and
delusions worsened in 10% of cases. Sleep disorder and
irritability were the main newly onset BPSD during pandemicSeptember 2020 | Volume 11 | Article 578015
Cagnin et al. BPSD During COVID Quarantine(Figure 2). In Table 2 are reported the prevalence of worsened
and new BPSD in the entire patients’ sample.
Prevalence of increased BPSD changes (worsened and/or new
symptoms) was similar across different classes of disease severity
defined by the Clinical Dementia Rating scale (CDR): mild=
CDR-1: 55.8%; moderate= CDR-2: 62.3%; severe CDR-3: 58.6%).
These results were maintained analyzing separately preexisting
and new BPSD. Instead, the type of BPSD changes varied
according to disease severity. Frequency distributions of
specific BPSD by CDR severity is represented in Figure 3.
Anxiety was most frequent in patients with mild dementia while
agitation and sleep disorder in patients with severe dementia.
Results of the multivariate analyses of neuropsychiatric
symptoms in different classes of disease severity showed an
increased risk of a wider pattern of BPSD in patients with
severe disease, while anxiety was associated with mild disease
severity (Figure 4).Profile of Neuropsychiatric Symptoms
Changes and Disease Type
Type of dementia was associated with different frequency
distribution of specific neuropsychiatric symptoms (Figure 5).
Worsening of sleep disorder and hallucinations were more
frequent in DLB compared to other types of dementia, while
worsening of wandering and change of appetite were more
frequently reported in FTD (Table 2 and Supplementary
Table 1). Anxiety was more frequently reported in AD and
DLB than in FTD and VD. On the contrary, some symptoms
increased similarly across disease groups such as apathy.
In the multivariate analyses the risk profiles of increased
BPSD were different according to type of dementia (Figure 6).
Having AD was associated with an increased risk of anxiety, DLB
with hallucinations and sleep disorder, and FTD with wandering
and change of appetite. On the opposite, AD and FTD had lower
risk of worsening hallucinations and FTD and VD to developFrontiers in Psychiatry | www.frontiersin.org 4worsening of anxiety. No significant associations were found
between type of dementia and type of new BPSD.
Profile of Neuropsychiatric Symptoms
Changes and Gender
Gender influenced the type of BPSD worsened during
quarantine. Symptoms of anxiety and depression were more
frequently reported in female patients, while apathy and
irritability in male patients (p<0.05) as shown in Figure 7.
In the multivariate analyses, increased risk of anxiety and
depression was significantly associated with female gender, while
apathy, irritability, and sleep disorder with male gender
(Figure 7).
Within the disease group, different frequency of specific
neuropsychiatric symptoms was observed in females compared
to males. Gender risk of BPSD by disease types showed different
associations which are summarized in Figure 8. In AD, the risk
of increased anxiety and depression was associated with being
female patients, while the risk of apathy was associated with male
patients. In DLB a higher risk of increased hallucinations was
associated with male gender, and sleep disorder.Caregivers’ Psychological Changes
Demographic, social, and psychological data of caregivers are
summarized in Table 3.
During quarantine a large range of stress-related feelings were
reported by 65.9% (n=3,240) of caregivers. Almost 46% had
symptoms of anxiety, followed by helplessness (34.2%), anguish
(29.3%), irritability (26.4%), abandonment (22%), and
depression (18.6%). There were not differences in frequency
distribution of caregiver’s psychological symptoms across types
of dementia.
Being females conferred an increased risk to develop anxiety
(OR 1.4, CI 1.3–1.6, p<0.0001), anguish (OR 1.5, CI 1.2–1.7,
p<0.0001), helplessness (OR 1.2, CI 1.1–1.4, p<0.01). AmongTABLE 1 | Demographic and clinical characteristics of patients affected by dementia.
Patients Total (n = 4913) AD (n = 3372) DLB (n = 360) FTD (n = 415) VD (n = 766)
Age (years, mean ± SD) 78.3 ± 8.2 78.3 ± 8 78 ± 7.3 72.3 ± 8.9 81.6 ± 7
Gender, female % (n) 59.7 (2.934) 63.5 (2.140) 42.2 (153) 46.7 (194) 58.4 (447)
Disease duration
(years, mean ± SD)
4.5 ± 3.1 4.6 ± 3.1 4.5 ± 3 4.8 ± 3.2 4.1 ± 2.9
Regional distribution in Italy % (n)
North 32.2 (1582) 26.5 (892) 35.3 (127) 47.5 (197) 47.8 (366)
Center 31.5 (1550) 34.1 (1151) 36.4 (132) 21.2 (88) 23.4 (179)
South/Islands 36.3 (1781) 39.4 (1328) 28.3 (102) 31.3 (130) 28.8 (221)
CDR stage % (n)
1 25.0 (1222) 24.3 (816) 26.3 (94) 23.4 (96) 28.4 (216)
2 47.8 (2334) 49.2 (1651) 41.9 (151) 48.6 (199) 43.8 (333)
3 27.2 (1325) 26.5 (885) 31.8 (114) 28.0 (115) 27.8 (211)
Worsening of BPSD, yes % (n) 51.9 (2542) 50.5 (1699) 63.8 (229) 55.3 (229) 50.3 (385)
Gender, female % (n) 57.9 (1472) 62.9 (1068) 38.4 (88) 45.4 (104) 55.1 (212)
Onset of new BPSD, yes % (n) 25.9 (1272) 26.7 (901) 23.3 (84) 21.9 (91) 25.6 (196)
Gender, female % (n) 56.7 (722) 59.8 (539) 41.7 (35) 41.8 (38) 56.1 (110)
BPSD-related drug modification, yes % (n) 27,6 (795) 25,9 (505) 33,6 (83) 32,1 (78) 29,1 (129)September 2020 | Volume 11 | AAD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; VD, vascular dementia; CDR, clinical dementia rating; BPSD, behavioral and psychological
symptoms of dementia.rticle 578015
Cagnin et al. BPSD During COVID Quarantinesocial characteristics, living with housemates reduced the
caregiver’s risk to develop symptoms of depression (OR 1.6, CI
0.5–0.7) and to conflict with the patient (OR 0.7, CI 0.6–
0.8) (p<0.0001).Frontiers in Psychiatry | www.frontiersin.org 5Presence of at least one caregiver’s stress-related symptom
was associated with increased risk of worsened preexisting BPSD
(OR 2.6, CI 2.3–13) and onset of new BPSD (OR 1.6, CI 1.4–
1.9) (p<0.0001).FIGURE 1 | Distribution of classes of behavioral and psychological symptoms (BPSD) burden defined as number of neuropsychiatric symptoms during quarantine
divided by disease type.FIGURE 2 | Frequency of behavioral and psychological symptoms (BPSD) worsened (dark blue) and newly ongoing (light blue) in the sample of patients with BPSD
changes (worsened and/or new onset, n = 2,929).September 2020 | Volume 11 | Article 578015
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In this nation-wide survey performed in Italy after 1 month from
the beginning of COVID-19 quarantine an increased burden of
neuropsychiatric symptoms was reported in approximately 60%
of community-dwelling persons affected by dementia by their
family caregivers. Treatment drug modifications were made in
27.6% of these patients. The most frequently reported BPSD were
symptoms of the anxiety-affective cluster. Profiles of BPSD
changes were influenced by type of dementia, disease severity,
and gender. Anxiety and depression were associated with a
diagnosis of AD, mild disease severity, and female gender.
Having DLB increased the risk of worsening hallucinations andFrontiers in Psychiatry | www.frontiersin.org 6sleep disorder, while FTD increased the risk of aberrant motor
behavior and change of appetite. Increased BPSD burden was
also associated with manifestation of psychological symptoms of
distress in two-thirds of caregivers. To our knowledge this is the
first survey assessing the impact of pandemic quarantine on the
mental health status of a large population of patients with
dementia and their caregivers.
Pandemic Quarantine as Stressor Event
Studies on mental health modifications induced by COVID-19
pandemic in healthy subjects demonstrated increased symptoms
of anxiety and depression (17–19). By now very few data are
available for persons with special needs and increased fragility asTABLE 2 | Frequency distribution of worsened preexisting and new behavioral and psychological symptoms of dementia (BPSD) in the entire patients’ sample and
divided by disease type.
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Cagnin et al. BPSD During COVID Quarantinepatients with dementia (20). A recent study evaluated BPSD
changes after 5 weeks of COVID-19 quarantine through the
Neuropsychiatric Inventory questionnaire in 40 patients with
AD: 20 with MCI and 20 with mild dementia (21). Worsening of
BPSD respect to baseline pre-lockdown assessment was reported
in 30% of patients and significant changes were found for apathy
(in both groups), anxiety in MCI, agitation, and aberrant motor
behavior in mild AD. We found a higher prevalence of increased
BPSD respect to what has previously been reported. In our study,Frontiers in Psychiatry | www.frontiersin.org 7family caregivers were enquired about any perceived changes of
patients’ neuropsychiatric symptoms; we did not use a
quantitative BPSD assessment and did not compare results
with a previous level of BPSD burden. Furthermore, diseases
with high risk of behavioral disorders such as FTD and DLB have
been included. Therefore, the higher burden of BPSD in our
study may be due to different study methodology and inclusion
of types of dementia other than AD. On the other hand, our
results confirmed the preliminary findings that apathy, agitation,FIGURE 3 | Frequency of neuropsychiatric symptoms in patients with behavioral and psychological symptoms (BPSD) changes (worsened and/or new onset,
n=2,929) divided by disease severity defined by Clinical Dementia Rating scale (CDR): mild: CDR-1 gray bar; moderate: CDR-2 orange bar and severe: CDR-3 blue
bar.FIGURE 4 | Multivariate analyses of behavioral and psychological symptoms (BPSD) changes associated to disease severity defined by CDR (Clinical Dementia
Rating) in mild (CDR-1), moderate (CDR-2), and severe (CDR-3).September 2020 | Volume 11 | Article 578015
Cagnin et al. BPSD During COVID QuarantineFIGURE 5 | Frequency of neuropsychiatric symptoms in patients with behavioral and psychological symptoms (BPSD) changes (worsened and/or new onset,
n=2,929) divided by disease type (blue bar AD, green DLB, yellow FTD, gray VD).FIGURE 6 | Multivariate analyses of worsened neuropsychiatric symptoms associated to disease types (diagnosis of AD, Alzheimer disease; DLB, dementia with
Lewy bodies; FTD, frontotemporal dementia; VD, vascular dementia).FIGURE 7 | (A) Graphical representation of frequency distribution of neuropsychiatric symptoms according to male (blue) and female (violet) gender in patients with
behavioral and psychological symptoms (BPSD) changes (worsened and/or new onset, n=2,929). (B) Type of neuropsychiatric symptoms significantly associated
with male gender (blue color) and female gender (violet) in the entire population of patients with dementia.Frontiers in Psychiatry | www.frontiersin.org September 2020 | Volume 11 | Article 5780158
Cagnin et al. BPSD During COVID Quarantineand anxiety are among the most frequently reported worsening
symptoms during quarantine in patients with dementia.
In our study we found increased neuropsychiatric symptoms
that rely on two different dimensions: those that represent a
behavioral reaction to quarantine and those that represent anFrontiers in Psychiatry | www.frontiersin.org 9increased level of those symptoms that are specific in the
different types of dementia. Increased symptoms of the
anxiety-affective cluster were common (prevalence ≥ 30% for
worsened irritability, agitation, and apathy and ≥ 20% of new
onset sleep disorder and irritability) and were homogeneouslyTABLE 3 | Demographic, social, and psychological characteristics of family caregivers.
Caregivers Total (n = 4913) AD (n = 3372) DLB (n = 360) FTD (n = 415) VD (n = 766)
Age (years, mean ± SD) 59.3 ± 13 59.3 ± 13.1 60.7 ± 12.7 59.1 ± 13.6 60 ± 12.4
Gender, female % (n) 53.9 (2649) 51.2 (1724) 66.4 (240) 55.4 (230) 59.4 (455)
Cohabitant caregiver, % (n) 58.9 (2876) 58.1 (1945) 63.5 (228) 69.6 (288) 54.4 (415)
Presence of housemates, % (n) 63.3 (3076) 63.1 (2104) 62.8 (224) 58.8 (241) 67.0 (507)
Degree of kinship, % (n)
Spouses 36.0 (1739) 35.0 (1160) 43.1 (154) 54.8 (221) 26.9 (204)
Son/daughter 54.5 (2636) 55.5 (1840) 48.7 (140) 37 (149) 62.5 (473)
Others 9.5 (460) 9.5 (318) 8.2 (29) 8.2 (33) 10.6 (80)
Change of conflicts, % (n)
Increased 22.6 (1105) 21.9 (735) 23.4 (84) 28.7 (119) 21.8 (167)
Decreased 8.0 (394) 8.5 (285) 7.2 (26) 7.0 (29) 7.1 (54)
Concern of patient’s health, % (n) 75.1 (3662) 75.2 (2518) 76.6 (272) 74.0 (304) 74.6 (568)
Stress-related feelings (%)
Anxiety 45.9 (2242) 46.1 (1543) 43.4 (155) 44.2 (182) 47.4 (362)
Depression 18.6 (902) 17.2 (573) 21.3 (76) 24.3 (101) 20.3 (152)
Anguish 29.3 (1422) 28.4 (943) 28.9 (103) 32.1 (133) 32.2 (243)
Irritability 26.4 (1285) 25.3 (843) 30.4 (109) 28.3 (117) 28.5 (216)
Abandonment 22.0 (1072) 21.2 (711) 22.2 (80) 24.8 (102) 23.6 (179)
Helplessness 34.2 (1672) 34.3 (1150) 33.0 (118) 33.7 (139) 34.9 (265)September 2020 | Volume 11 | AAD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; VD, vascular dementia.FIGURE 8 | Type of neuropsychiatric symptoms significantly associated with male gender (blue circles) and female gender (violet circles) by disease type.rticle 578015
Cagnin et al. BPSD During COVID Quarantinereported across disease types. This finding is in line with many
observations of increased psychological symptoms of anxiety and
depression during COVID-19 quarantine in healthy subjects and
give support to the notion that quarantine acts as a stressor event
that induces symptoms similar of those reported in the post-
traumatic stress disorder (PTSD) (22–24). Indeed, quarantine due
to pandemic involves different social, emotional, psychological, and
physical modifications, each one with a potential contribution to
increase distress. Quarantine determines social isolation and feeling
of loneliness, conditions which have been demonstrated to induce
psychiatric and physical alterations in healthy individuals (25, 26).
The pandemic in itself can contribute to trigger fear and contagion
phobia. In persons with dementia, the increase of anxiety-related
BPSD during quarantine may be interpreted as a response to a
stressor event and represent a PTSD-like condition. A confirm of
such speculation derives from the observation that anxiety and
depression increased more in patients with mild to moderate level
of severity that could still present a post-traumatic reaction.
Patients with dementia have pre-trauma risk factors for the
development of PTSD such as increased central nervous system
sensitization due to preexisting anxiety and hyperarousal, and
lower hippocampal volume (27). Neuroimaging studies showed
that the neuro-anatomical correlates of PTSD are decreased
volume of the hippocampus and anterior cingulate cortex which
are target regions of neuropathology in AD, DLB, and FTD (27).
On the other hand, there are emerging evidence of a higher risk to
develop cognitive decline in patients with PTSD (15).We could
here hypothesize that patients with mild to moderate level of
dementia are at higher risk respect to healthy subjects to manifest a
variety of anxiety-related symptoms triggered in response to
isolations and restrains imposed by quarantine and that this
condition may render these patients more vulnerable to the
development of a PTSD-like symptomatology. This in turn
might potentially worsen the trajectory of cognitive decline.
Pandemic Quarantine as a Model of
“Deprivation Syndrome”
In the last years the research field of dementia has invested a lot
in demonstrating the value of cognitive, social, and physical
stimulation in the prevention of cognitive decline, the
modulation of the trajectory of clinical worsening in the early
stage of the disease and containment of the neuropsychiatric
burden (28–30). Based on the results of these studies many
countries have started population programs of multimodal
stimulation for persons at risk of dementia or with initial
cognitive decline (31). During quarantine any formal and
informal cognitive stimulation programs have been suddenly
stopped. In addition, informal multidimensional stimulation
derived by performances of outdoor day to day routines and
maintenance of social contacts have been also markedly reduced
for everyone.
Reduction of social contacts, cognitive stimulation, and physical
activity can be viewed as a paradigm of “de-stimulation” or even as
a model of “deprivation syndrome.” The effects of environmental
deprivation defined as lack of inputs from the environment have
been studied in young and adolescents for which deprivationFrontiers in Psychiatry | www.frontiersin.org 10influences subsequent psychopathology and alters cognitive
developmental abilities (32, 33). Translating this term into old-
age psychiatry and applying it to the topic of our study, quarantine
may be viewed as an ecological experiment on the effects of acute
interruption and deprivation of social, cognitive, and physical
stimulation. This condition may affect cognitive and physical
domains but also neuropsychiatric symptoms, reverting the well-
known effects on global health of multidimensional stimulation.
Obviously, this condition might be considered a sort of “partial
deprivation” as family members continue to play an important,
although limited, role on the social interaction with demented
subjects. We can hypothesize that increase apathy, observed in
approximately 35% of patents with BPSD changes and equally
distributed across the disease types, might be a surrogate
manifestation of a complex and global interaction of cognitive,
physical, and emotional down-regulation. Apathy, in fact, may have
a cognitive, emotional, and physical component and each type of
apathy has defined neuro-anatomical correlates targeting
prefrontal, dorsolateral, and motor cortex other than striatum
(34, 35).
Modulators of the Profile of Behavioral
and Psychological Symptoms of Dementia
Changes
Factors modulating the profile of increased BPSD were disease
type, disease severity, and gender. Although worsening of some
BPSD such as irritability and apathy are transdiagnostic, the type
of neurodegenerative disease confers different risk of specific
BPSD changes, such as hallucinations and sleep disorder for DLB
or appetite change for FTD. Exposure to stressful events can
therefore increase those neuropsychiatric symptoms for which
patients with dementia are inherently more vulnerable due to the
neuropathology of dementia.
Presence of visual hallucinations and alterations of sleep and
wake are specific features of DLB (36). In DLB there is a higher
burden of behavioral symptoms than in AD and high frequency
of anxiety and depression symptoms (37, 38). On a substrate of a
disease targeting the sleep-wake cycle and attentional abilities,
the increase of stress-related symptoms may further worsen an
efficient sleep pattern and impair attention and reality monitoring
checking, with subsequent increase of hallucinations.
As regard as FTD, eating disorders are key symptoms in the
diagnosis of the behavioral variant FTD, are disease specific, and
are characterized by changes in dietary preferences toward
carbohydrates, increased appetite, binge-eating behavior, and
altered eating habits (39). We recognize the limit of this study
related to the genericity of the question investigating changes of
appetite without specifying whether it was a variation of increase
or decrease appetite. Aberrant motor behavior may be explained
as expression of reduced inhibitory control, lack of adherence to
imposed societal rules and poor judgment of risks.
Disease severity was not associated with prevalence of
increased BPSD burden (preexisting or new symptoms) but
with profile of BPSD changes. We confirmed previous findings
from the study by Lara et al. that showed increased anxiety in
MCI patients and apathy in mild-moderate AD patients afterSeptember 2020 | Volume 11 | Article 578015
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of the traumatic event and with higher limitations respect to pre-
pandemic lifestyle may be at higher risk to develop stress-related
symptoms. With disease progression, the heterogeneity of BPSD
manifestations reflects the increased multifactorial complexity
(40, 41).
Gender effect on the type of BPSD has been demonstrated in
AD, with females having more frequently psychotic symptoms
and depression (42–44), and males presenting more frequently
apathy and aggression (45). Different presentations of BPSD
according to gender have already been described and most
studies report the prevalence of anxiety and depression among
female patients. This gender effect is more evident in mild to
moderate stage of the disease and disappear in advanced stage
(46). Some other authors report different manifestation of BPSD
also in advanced stages of disease with males that exhibited more
apathy and sexually inappropriate behavior and females
exhibiting more anxiety and sadness (47). Our data are in line
with these findings confirming that symptoms of depression and
anxiety are more prevalent in women, particularly in the mild
stages of the disease (43, 46, 48), while apathy and irritability are
more prevalent in males (45).
Caregivers Distress and Influence on
Behavioral and Psychological Symptoms
of Dementia
BPSD are the most stressful aspects strongly reducing quality of
life for both patients and caregivers. Anxiety and depression
accompany caregivers along the entire disease course (49) and
caregiver burden is a well-known socially and scientifically
recognized aspect (50). Caregiving burden is known to be
higher and heavier for women than men (51). In our study we
found an increase prevalence of symptoms of anxiety, feeling of
helplessness, and anguish reported by caregivers. Increased
concern for patient health and increased familial conflicts were
also reported. Presence of housemates reduced the risk of
depression and conflicts thus indicating that caregiver burden
may be mitigated by contrasting loneliness and supporting needs
of caring with a network of helps (52).
We found an association between psychological symptoms of
anxiety and depression in caregivers and increased BPSD burden.
From the results of our survey we could not address the issue of
whether increased BPSD are the cause or consequence of caregiver
distress, particularly during quarantine when both counterparts
have been exposed to similar stressor conditions.
Strengths and Limitations
This is the first survey addressing prevalence and type of increase in
neuropsychiatric symptoms as acute consequence of imposed
isolation due to COVID-19 quarantine in a large population of
patients affected by dementia. The sample is large, representative of
the most frequent forms of dementia and balanced across groups as
far as demographic and clinical variables. Considerations drawn
from the results of this study could therefore be extended to
community-dwelling subjects affected by dementia. Limitations
included the lack of standardized assessment using formalFrontiers in Psychiatry | www.frontiersin.org 11neuropsychiatric rating scales and lack of information on
previous BPSD severity and type. This was due to the narrative
nature of phone-based interview, the organizational constrains due
to the emergency setting, and the need to recruit a large sample in a
short time to monitor acutely the neuropsychiatric modifications
during quarantine. Moreover, the interview was delivered to
caregivers and therefore reports could be influenced by their
emotional status and level of distress. However, there are studies
confirming the reliability of caregivers reporting BPSD in dementia
(53). Another limitation is the absence of information on type of
drug prescription modification made in more than one-quarter of
patients with BPSD changes. This would have been interesting
since use of some drugs classes, such as antipsychotics, modify the
risk of stroke and mortality and since an untailored therapeutic
plan during quarantine could be partially responsible for
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